Merrimack Pharmaceuticals, Inc. (MACK)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
5.54+0.42 (+8.20%)
At close: 4:00 PM EDT

5.58 0.04 (0.72%)
After hours: 5:25 PM EDT

People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close5.12
Bid5.54 x 700
Ask5.58 x 900
Day's Range5.03 - 5.67
52wk Range4.39 - 10.18
1y Target EstN/A
Market Cap716M
P/E Ratio (ttm)-3.63
Avg Vol (3m)2,790,880
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Capital Cube2 days ago

    ETF’s with exposure to Merrimack Pharmaceuticals, Inc. : October 19, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to Merrimack Pharmaceuticals, Inc. Here are 5 ETF’s with the largest exposure to MACK-US. Comparing the performance and risk of Merrimack Pharmaceuticals, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Investopedia3 days ago

    Merrimack's Cancer Drug Wins EU Nod (MACK, SHPG)

    A pancreatic cancer drug jointly developed by Merrimack Pharmaceuticals and its UK partner, Shire Plc, has been approved for marketing in Europe.

  • American City Business Journals3 days ago

    ​Pancreatic cancer drug developed in the Bay State approved in Europe

    A new pancreatic cancer drug in Europe that was developed by a local biotech company has been approved to be sold in Europe by a different company based in Lexington. Lexington-based Shire (SHPG) announced early this morning that Onivyde, a targeted version of a chemotherapy drug that became the first on the market for Cambridge-based Merrimack Pharmaceuticals (MACK) last year, has been granted marketing authorization by the European Commission. Similar to its U.S. approval in October 2015, the drug is to be used after a tumor has become resistant to gemcitabine, a 20-year-old cancer drug sold under the name Gemzar by Eli Lilly (LLY).